The network structure of hematopoietic cancers.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 11 2023
13 11 2023
Historique:
received:
31
05
2023
accepted:
03
11
2023
medline:
16
11
2023
pubmed:
15
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Hematopoietic cancers (HCs) are a heterogeneous group of malignancies that affect blood, bone marrow and lymphatic system. Here, by analyzing 1960 RNA-Seq samples from three independent datasets, we explored the co-expression landscape in HCs, by inferring gene co-expression networks (GCNs) with four cancer phenotypes (B and T-cell acute leukemia -BALL, TALL-, acute myeloid leukemia -AML-, and multiple myeloma -MM-) as well as non-cancer bone marrow. We characterized their structure (topological features) and function (enrichment analyses). We found that, as in other types of cancer, the highest co-expression interactions are intra-chromosomal, which is not the case for control GCNs. We also detected a highly co-expressed group of overexpressed pseudogenes in HC networks. The four GCNs present only a small fraction of common interactions, related to canonical functions, like immune response or erythrocyte differentiation. With this approach, we were able to reveal cancer-specific features useful for detection of disease manifestations.
Identifiants
pubmed: 37963971
doi: 10.1038/s41598-023-46655-2
pii: 10.1038/s41598-023-46655-2
pmc: PMC10645882
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19837Informations de copyright
© 2023. The Author(s).
Références
Genome Res. 2011 Dec;21(12):2213-23
pubmed: 21903743
Cancers (Basel). 2022 Jun 15;14(12):
pubmed: 35740621
BMC Bioinformatics. 2011 Dec 17;12:480
pubmed: 22177264
Semin Hematol. 2011 Jan;48(1):4-12
pubmed: 21232653
Front Genet. 2020 Nov 03;11:578679
pubmed: 33240325
Cancer Res. 2007 Dec 1;67(23):11393-401
pubmed: 18056467
Cell. 2012 Jun 22;149(7):1622-34
pubmed: 22726445
Brief Bioinform. 2018 Jul 20;19(4):575-592
pubmed: 28077403
Sci Rep. 2017 May 11;7(1):1760
pubmed: 28496157
Biochimie. 2012 Nov;94(11):2219-30
pubmed: 22609632
Front Physiol. 2018 Oct 11;9:1423
pubmed: 30364267
Cell Death Dis. 2022 Feb 24;13(2):178
pubmed: 35210406
Front Physiol. 2017 Nov 17;8:915
pubmed: 29204123
Front Genet. 2021 Apr 20;12:629475
pubmed: 33959148
Blood Adv. 2022 Jul 26;6(14):4093-4097
pubmed: 35482550
Genes (Basel). 2019 Oct 30;10(11):
pubmed: 31671657
J Hepatol. 2011 Jul;55(1):111-9
pubmed: 21419759
Front Oncol. 2020 Jul 24;10:1232
pubmed: 32850369
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
BMC Bioinformatics. 2006 Mar 20;7 Suppl 1:S7
pubmed: 16723010
Oncogene. 2015 Jun;34(25):3215-25
pubmed: 25220419
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Oncol. 2022 Jul 22;12:934711
pubmed: 35936681
Front Oncol. 2020 Sep 25;10:582451
pubmed: 33102238
Front Genet. 2021 Mar 10;12:625741
pubmed: 33777098
Cancer Treat Res. 2016;169:3-12
pubmed: 27696254
Front Physiol. 2016 Nov 22;7:568
pubmed: 27920729
PLoS Comput Biol. 2020 Oct 23;16(10):e1008239
pubmed: 33095781
Comput Biol Chem. 2015 Dec;59 Pt B:67-77
pubmed: 26362298
J Immunol. 2002 Oct 15;169(8):4213-21
pubmed: 12370351
PLoS Comput Biol. 2013;9(3):e1002955
pubmed: 23505361
Immunity. 2002 Aug;17(2):179-89
pubmed: 12196289
Front Immunol. 2019 Jan 29;10:56
pubmed: 30761130
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Front Genet. 2022 Apr 01;13:806607
pubmed: 35432489
Cell. 2011 Oct 14;147(2):370-81
pubmed: 22000015
Cancer Discov. 2021 May;11(5):1082-1099
pubmed: 33408242
Sci Rep. 2017 Oct 19;7(1):13534
pubmed: 29051564
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Front Oncol. 2021 Nov 17;11:726493
pubmed: 34868919
Wellcome Open Res. 2017 Feb 10;2:9
pubmed: 28492065
Genome Res. 2007 Jun;17(6):839-51
pubmed: 17568002
Genome Biol. 2021 Jan 7;22(1):21
pubmed: 33413539
Best Pract Res Clin Haematol. 2005;18(4):493-507
pubmed: 16026733